CDER’s new proposal to withdraw the accelerated acceptance of Makena (HPC) was based mostly on a large randomized demo that unsuccessful to here substantiate the good thing about this drug to newborns or reduce the potential risk of PTB. In making the choice to suggest Makena’s withdrawal, CDER also reviewed final results from prior reports o